This randomized trial demonstrates that the addition of cetuximab to CAPIRI or CAPOX is effective and safe in first-line treatment of mCRC. In the analyzed regimens, ORR and PFS did not differ according to KRAS gene mutation status.
A sizeable percentage of patients receiving conventional medical treatment also use unconventional medicine (UM). Surveys indicate that the prevalence of and motivation for the pursuit of the different approaches of UM is subject to individual, geographical, cultural and disease-related factors. We were interested in the concurrent use of and attitudes towards UM in patients who underwent conventional medical treatment in our oncologically orientated department of internal medicine in a regionally dominant teaching hospital. A representative sample (n = 131) of all inpatients and outpatients receiving treatment in the department or in its oncological/haematological outpatient clinic were asked to participate in a cross-sectional interview study on the use of unconventional therapies. In all, 128 patients (97.7%) agreed to participate in the study, and 65% of these patients were suffering from malignancies. Use of unconventional treatment was reported by 24% of all patients for their current medical problem, and 16% of the remaining patients had been thinking of adjunctive use. The use of UM was significantly higher among oncological patients (32%), and among oncological outpatients in particular (50%), than among patients with acute or chronic non-malignant diseases. Female patients predominated among the users of UM (71%). UM mainly took the form of various pharmacological and dietary approaches. Patients availing themselves of UM most frequently identified physicians (41%) as the source of treatment recommendation. Only 18% of the users of UM relied on these methods as a chance of cure. Use of UM was not generally motivated by dissatisfaction with conventional medical care. Only half the users informed their hospital physician of their adjunctive use of UM. Nearly 2 out of 3 of the users contended that UM had contributed to a mild or distinct improvement in their physical or psychological wellbeing. The use of UM in modern health care systems represents a widespread and intricate phenomenon, which cannot be understood by focusing exclusively on the objective assessment of clinical efficacy. Use of UM may be related more to a disease's unfavourable attribution than to its medically expected outcome. Coherence with individual illness paradigms and perceived efficacy are apparently important factors in patients' use of UM. These subjective aspects need to be recognised in caring patient-doctor communication.
Purpose. To report on a telephone consultation service with
cancer patients and their relatives about complementary and alternative medicine
(CAM) between 1999 and 2011. Methods. We offered a
Germany-wide, free-of-charge telephone consultation service about CAM led by
oncology clinicians from a comprehensive cancer center. The consultations
followed a patient-centered approach with the aim to provide guidance and
evidence-based information. Sociodemographic, disease-related data as well as
information about the consultations’ content were collected in a standardized
manner, and feedback questionnaires were sent out immediately after the
consultations. Results. Overall, 5269 callers from all over
Germany used the service (57% patients, 43% relatives). The “big 4” cancer types
(breast, gastrointestinal, prostate, and lung) accounted for 55% of all calls.
In 67% of calls, patients had just received the diagnosis or commenced
anticancer therapy; 69% of patients had advanced or metastatic diseases. More
than half of the callers (55%) had vague concerns like “what else can I
do?” rather than specific questions related to CAM. The
consultations covered a broad spectrum of issues from CAM therapies to cancer
treatment and measures supportive of health, nutrition, and psychosocial
support. Callers highly valued the service. Conclusions.
Consulting about CAM addresses important unmet needs from cancer patients and
their relatives. It provides clinicians with the opportunity to engage in open
and supportive dialogues about evidence-based CAM to help with symptom
management, psychological support, and individual self-care. Consulting about
CAM cannot be separated from consulting about conventional care and should be
provided from the beginning of the cancer journey.
The effects of recombinant thrombopoietin (TPO) alone and in combination with erythropoietin (EPO) and early-acting cytokines such as interleukin 3 (IL-3), stem cell factor (SCF) and GM-CSF on highly purified mobilized human CD34 + progenitor cells were studied in a serum-depleted culture system. Eight leukapheresis samples were cultured for seven days and analyzed; aliquots were replated and re-evaluated on day 12. Three-color flow cytometry was used together with morphologic analysis to determine proliferation and megakaryocytic or erythroid maturation.TPO alone was sufficient for cell survival and proliferation in serum-depleted medium. In the absence of other growth factors, almost all CD34 + cells differentiated along the megakaryocytic pathway within 12 days. Concomitantly, the progenitor cells gradually acquired the morphologic features of mature megakaryocytes. After exposure to TPO for one week, 50% of the cells
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.